Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases

Journal of Clinical Microbiology

Volumn 53, Issue 5, 2015, Pages 1473-1483

  Witney, Adam A ^a   Gould, Katherine A ^a   Arnold, Amber ^b   Coleman, David ^a   Delgado, Rachel ^b   Dhillon, Jasvir ^a   Pond, Marcus J ^a   Pope, Cassie F ^b   Planche, Tim D ^a,b   Stoker, Neil G ^a   Cosgrove, Catherine A ^a,b   Butcher, Philip D ^a   Harrison, Thomas S ^a,b   Hinds, Jason ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CLINICAL ARTICLE; CLINICAL DECISION MAKING; DRUG WITHDRAWAL; GENE MUTATION; GYRA GENE; GYRB GENE; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PNCA GENE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPUTUM CULTURE; TUBERCULOUS SPONDYLITIS; WHOLE GENOME SEQUENCING; BACTERIAL GENOME; DNA SEQUENCE; DRUG EFFECTS; ENGLAND; EVALUATION STUDY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MOLECULAR DIAGNOSIS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; TEACHING HOSPITAL; TIME FACTOR;

MYCOBACTERIUM TUBERCULOSIS;

BACTERIOLOGICAL TECHNIQUES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENES, BACTERIAL; GENOME, BACTERIAL; GENOTYPE; HOSPITALS, TEACHING; HUMANS; LONDON; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; MYCOBACTERIUM TUBERCULOSIS; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

EID: 84928019939     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02993-14     Document Type: Article

References (47)

1. WHO. 2014. Global tuberculosis report 2014. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809-eng.pdf?ua-1.
2. WHO. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809-eng.pdf?ua-1.
3. Health Protection Agency, Public Health England. 2013. Tuberculosis in the UK: 2013 report. Public Health England, London, United Kingdom. https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/325632/TB-in-the-UK.pdf.
4. Lange C, Abubakar I, Alffenaar J-WC, Bothamley G, Caminero JA, Carvalho ACC, Chang K-C, Codecasa L, Correia A, Crudu V, Davies P, Dedicoat M, Drobniewski F, Duarte R, Ehlers C, Erkens C, Goletti D, Günther G, Ibraim E, Kampmann B, Kuksa L, de Lange W, van Leth F, van Lunzen J, Matteelli A, Menzies D, Monedero I, Richter E, Rüsch-Gerdes S, Sandgren A, Scardigli A, Skrahina A, Tortoli E, Volchenkov G, Wagner D, van der Werf MJ, Williams B, Yew W-W, Zellweger J-P, Cirillo DM, TBNET. 2014. Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 44:23-63. http://dx.doi.org/10.1183/09031936.00188313.
5. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, Kop J, Owens MR, Rodgers R, Banada P, Safi H, Blakemore R, Lan NTN, Jones-López EC, Levi M, Burday M, Ayakaka I, Mugerwa RD, McMillan B, Winn-Deen E, Christel L, Dailey P, Perkins MD, Persing DH, Alland D. 2010. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48:229-237. http://dx.doi.org/10.1128/JCM.01463-09.
6. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. 2005. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 43:3699-3703. http://dx.doi.org/10.1128/JCM.43.8.3699-3703 .2005.
7. Hillemann D, Rüsch-Gerdes S, Richter E. 2009. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 47:1767-1772. http://dx.doi.org/10 .1128/JCM.00081-09.
8. Hillemann D, Hoffner S, Cirillo D, Drobniewski F, Richter E, Rüsch-Gerdes S, the Baltic-Nordic TB-Laboratory Network, TB PAN-NET, ECDC ERLN-TB Networks. 2013. First evaluation after implementation of a quality control system for the second line drug susceptibility testing of Mycobacterium tuberculosis joint efforts in low and high incidence countries. PLoS One 8:e76765. http://dx.doi.org/10 .1371/journal.pone.0076765.
9. Walker TM, Ip CLC, Harrell RH, Evans JT, Kapatai G, Dedicoat MJ, Eyre DW, Wilson DJ, Hawkey PM, Crook DW, Parkhill J, Harris D, Walker AS, Bowden R, Monk P, Smith EG, Peto TEA. 2013. Wholegenome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis 13:137-146. http://dx .doi.org/10.1016/S1473-3099(12)70277-3.
10. Walker TM, Monk P, Smith EG, Peto TEA. 2013. Contact investigations for outbreaks of Mycobacterium tuberculosis: advances through whole genome sequencing. Clin Microbiol Infect 19:796-802.
11. Walker TM, Lalor MK, Broda A, Saldana Ortega L, Morgan M, Parker L, Churchill S, Bennett K, Golubchik T, Giess AP, Del Ojo Elias C, Jeffery KJ, Bowler ICJW, Laurenson IF, Barrett A, Drobniewski F, McCarthy ND, Anderson LF, Abubakar I, Thomas HL, Monk P, Smith EG, Walker AS, Crook DW, Peto TEA, Conlon CP. 2014. Assessment of Mycobacterium tuberculosis transmission in Oxfordshire, UK, 2007-12, with whole pathogen genome sequences: an observational study. Lancet Respir Med 2:285-292. http://dx.doi.org/10.1016/S2213-2600(14)70027-X.
12. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, Corander J, Bryant J, Parkhill J, Nejentsev S, Horstmann RD, Brown T, Drobniewski F. 2014. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet 46:279-286. http://dx.doi.org/10.1038/ng.2878.
13. Köser C, Bryant MJ, Becq J, Török ME, Ellington MJ, Marti-Renom MA, Carmichael AJ, Parkhill J, Smith GP, Peacock SJ. 2013. Wholegenome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 369:290-292. http://dx.doi.org/10.1056/NEJMc1215305.
14. Thorpe TC, Wilson ML, Turner JE, DiGuiseppi JL, Willert M, Mirrett S, Reller LB. 1990. BacT/Alert: an automated colorimetric microbial detection system. J Clin Microbiol 28:1608-1612.
15. Drobniewski F, Caws M, Gibson A, Young D. 2003. Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis 3:141-147. http://dx.doi.org/10.1016/S1473-3099(03)00544-9.
16. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078-2079. http://dx.doi.org/10.1093/bioinformatics/btp352.
17. Stamatakis A. 2006. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics 22:2688-2690. http://dx.doi.org/10.1093/bioinformatics/btl446.
18. Yang Z. 2007. PAML 4: phylogenetic analysis by maximum likelihood. Mol Biol Evol 24:1586-1591. http://dx.doi.org/10.1093/molbev/msm088.
19. Li H. 2013. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv:1303.3997. http://arxiv.org/abs/1303.3997.
20. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. 2009. Tuberculosis drug resistance mutation database. PLoS Med 6:e2. http://dx.doi.org/10.1371/journal.pmed.1000002.
21. Feasey NA, Pond M, Coleman D, Solomon AW, Cosgrove CA, Delgado R, Butcher PD, Mitchison DA, Harrison T. 2011. Moxifloxacin and pyrazinamide susceptibility testing in a complex case of multidrugresistant tuberculosis. Int J Tuberc Lung Dis 15:417-420.
22. Zimic M, Fuentes P, Gilman RH, Gutiérrez AH, Kirwan D, Sheen P. 2012. Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis 92:84-91. http://dx.doi .org/10.1016/j.tube.2011.09.002.
23. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. 2012. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 7:e39754. http://dx .doi.org/10.1371/journal.pone.0039754.
24. Matrat S, Veziris N, Mayer C, Jarlier V, Truffot-Pernot C, Camuset J, Bouvet E, Cambau E, Aubry A. 2006. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob Agents Chemother 50:4170-4173. http://dx.doi.org/10.1128/AAC.00944-06.
25. Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, Musser JM. 1997. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci U S A 94:9869-9874. http://dx .doi.org/10.1073/pnas.94.18.9869.
26. Daum LT, Rodriguez JD, Worthy Sa, Ismail NA, Omar SV, Dreyer AW, Fourie PB, Hoosen AA, Chambers JP, Fischer GW. 2012. Nextgeneration Ion Torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains. J Clin Microbiol 50:3831-3837. http://dx .doi.org/10.1128/JCM.01893-12.
27. World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2011/97 89241501583-eng.pdf.
28. Okamoto S, Tamaru A, Nakajima C, Nishimura K, Tanaka Y, Tokuyama S, Suzuki Y, Ochi K. 2007. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol Microbiol 63:1096-1106. http://dx.doi.org/10.1111/j.1365-2958.2006.05585.x.
29. Maus CE, Plikaytis BB, Shinnick TM. 2005. Molecular analysis of crossresistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49:3192-3197. http://dx.doi.org/10.1128/AAC.49.8.3192-3197.2005.
30. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. 2012. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 7:e33275. http://dx.doi.org/10.1371/journal.pone.0033275.
31. Rengarajan J, Sassetti CM, Naroditskaya V, Sloutsky A, Bloom BR, Rubin EJ. 2004. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol Microbiol 53:275-282. http://dx.doi.org/10.1111/j.1365-2958.2004.04120.x.
32. Gagneux S. 2012. Host-pathogen coevolution in human tuberculosis. Philos Trans R Soc Lond B Biol Sci 367:850-859. http://dx.doi.org/10 .1098/rstb.2011.0316.
33. Bryant JM, Harris SR, Parkhill J, Dawson R, Diacon AH, van Helden P, Pym A, Mahayiddin AA, Chuchottaworn C, Sanne IM, Louw C, Boeree MJ, Hoelscher M, McHugh TD, Bateson ALC, Hunt RD, Mwaigwisya S, Wright L, Gillespie SH, Bentley SD. 2013. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir Med 1:786-792. http://dx.doi .org/10.1016/S2213-2600(13)70231-5.
34. Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T, Liu Z, Li C, Galwey N, Deng J, Zhou Y, Zhu Y, Gao Y, Wang T, Wang S, Huang Y, Wang M, Zhong Q, Zhou L, Chen T, Zhou J, Yang R, Zhu G, Hang H, Zhang J, Li F, Wan K, Wang J, Zhang X-E, Bi L. 2013. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet 45:1255-1260. http://dx.doi.org/10.1038/ng.2735.
35. Stucki D, Malla B, Hostettler S, Huna T, Feldmann J, Yeboah-Manu D, Borrell S, Fenner L, Comas I, Coscolla M, Gagneux S. 2012. Two new rapid SNP-typing methods for classifying Mycobacterium tuberculosis complex into the main phylogenetic lineages. PLoS One 7:e41253. http://dx.doi.org/10.1371/journal.pone.0041253.
36. Tsolaki AG, Gagneux S, Pym AS, Goguet de la Salmoniere Y-OL, Kreiswirth BN, Van Soolingen D, Small PM. 2005. Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of Mycobacterium tuberculosis. J Clin Microbiol 43:3185-3191. http://dx.doi.org/10.1128/JCM.43.7.3185-3191.2005.
37. Bosne-David S, Barros V, Verde SC, Portugal C, David HL. 2000. Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. J Antimicrob Chemother 46:391-395. http://dx.doi.org/10.1093/jac/46.3 .391.
38. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51:42-49.
39. Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, Gillis TP. 1998. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42:1853-1857.
40. Shafer RW. 2006. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194(Suppl 1):S51-S58. http://dx.doi.org/10.1086/505356.
41. Köser CU, Ellington MJ, Cartwright EJP, Gillespie SH, Brown NM, Farrington M, Holden MTG, Dougan G, Bentley SD, Parkhill J, Peacock SJ. 2012. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog 8:e1002824. http://dx.doi.org/10.1371/journal.ppat.1002824.
42. Kato-Maeda M, Shanley CA, Ackart D, Jarlsberg LG, Shang S, Obregon-Henao A, Harton M, Basaraba RJ, Henao-Tamayo M, Barrozo JC, Rose J, Kawamura LM, Coscolla M, Fofanov VY, Koshinsky H, Gagneux S, Hopewell PC, Ordway DJ, Orme IM. 2012. Beijing sublineages of Mycobacterium tuberculosis differ in pathogenicity in the guinea pig. Clin Vaccine Immunol 19:1227-1237. http://dx.doi.org/10.1128/CVI.00250-12.
43. Werngren J, Hoffner SE. 2003. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J Clin Microbiol 41:1520-1524. http://dx .doi.org/10.1128/JCM.41.4.1520-1524.2003.
44. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35: 907-914.
45. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, Savine E, de Haas P, van Deutekom H, Roring S, Bifani P, Kurepina N, Kreiswirth B, Sola C, Rastogi N, Vatin V, Gutierrez MC, Fauville M, Niemann S, Skuce R, Kremer K, Locht C, van Soolingen D. 2006. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 44:4498-4510. http://dx.doi.org/10.1128/JCM.01392-06.
46. Resch SC, Salomon JA, Murray M, Weinstein MC. 2006. Costeffectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3:e241. http://dx.doi.org/10.1371/journal.pmed.0030241.
47. Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, Eiglmeier K, Garnier T, Gutierrez C, Hewinson G, Kremer K, Parsons LM, Pym AS, Samper S, van Soolingen D, Cole ST. 2002. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A 99:3684-3689. http://dx.doi.org/10.1073/pnas.052548299.